What question did this study set out to answer?

April 3, 2026Journal of Cystic Fibrosis0 citationsOpen Access

Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis

EBEva Van BraeckelGhent University Hospital ABAndrew T. BraunUniversity of Wisconsin–Madison NSNicholas J. SimmondsGuy's and St Thomas' NHS Foundation Trust

Key Points

To evaluate the impact of elexacaftor/tezacaftor/ivacaftor on cough frequency, physical activity, and sleep quality in cystic fibrosis.
Conducted a 13-week, phase 3b, open-label study.
Participants included adolescents and adults with cystic fibrosis previously na?ve to ELX/TEZ/IVA.
Utilized wearable cough monitors and actigraphy sensors to measure outcomes.
Notable improvement in cough frequency observed.
Participants exhibited increased physical activity levels.
Enhancements in sleep quality were reported.

Abstract

Background: Cystic fibrosis (CF) transmembrane conductance regulator modulators improve lung function, however, effects on cough frequency, physical activity, and sleep have not been assessed in clinical studies.Methods: After a 12-week, phase 4 pilot feasibility study, we conducted a 13-week, phase 3b, open-label study in participants with CF aged 12 years previously nave to elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) to assess the effects of ELX/TEZ/IVA on cough frequency, physical activity, and sleep using wearable cough monitors and actigraphy sensors .

问 AI

Bookmark

View Full Paper